IS7456A - Fosfat forlyf flúoróoxindóla - Google Patents

Fosfat forlyf flúoróoxindóla

Info

Publication number: IS7456A
Authority: IS; Iceland
Prior art keywords: fluorooxindole; phosphate prodrugs; prodrugs; phosphate
Prior art date: 2002-03-20

Application number

IS7456A

Other languages

English (en)

Inventor

W. Gillman Kevin

Hewawasam Piyasena

D. Schmitz William

D. Lopez Omar

E. Starrett John

P. Provencal David

Original Assignee

Bristol-Myers Squibb Company

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-03-20

Filing date

2004-09-17

Publication date

2004-09-17

2004-09-17 Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company

2004-09-17 Publication of IS7456A publication Critical patent/IS7456A/is

Links

SCRXASNUPJPFGP-UHFFFAOYSA-N 1-fluoro-3h-indol-2-one Chemical compound C1=CC=C2N(F)C(=O)CC2=C1 SCRXASNUPJPFGP-UHFFFAOYSA-N 0.000 title 1
229910019142 PO4 Inorganic materials 0.000 title 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 title 1
239000010452 phosphate Substances 0.000 title 1
229940002612 prodrug Drugs 0.000 title 1
239000000651 prodrug Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/572—Five-membered rings
- C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/54—Quaternary phosphonium compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Reproductive Health (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Pain & Pain Management (AREA)
Cardiology (AREA)
Endocrinology (AREA)
Gynecology & Obstetrics (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Toxicology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

IS7456A 2002-03-20 2004-09-17 Fosfat forlyf flúoróoxindóla IS7456A (is)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US36601002P	2002-03-20	2002-03-20
PCT/US2003/008613 WO2003080047A1 (en)	2002-03-20	2003-03-20	Phosphate prodrugs of fluorooxindoles

Publications (1)

Publication Number	Publication Date
IS7456A true IS7456A (is)	2004-09-17

Family

ID=28454740

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IS7456A IS7456A (is)	2002-03-20	2004-09-17	Fosfat forlyf flúoróoxindóla

Country Status (21)

Country	Link
US (1)	US6930100B2 (is)
EP (1)	EP1485085A4 (is)
JP (1)	JP4359150B2 (is)
KR (1)	KR100951499B1 (is)
CN (1)	CN100384820C (is)
BR (1)	BR0308737A (is)
CA (1)	CA2479256A1 (is)
CO (1)	CO5611143A2 (is)
GE (1)	GEP20074230B (is)
HR (1)	HRP20040853A2 (is)
IL (2)	IL164022A0 (is)
IS (1)	IS7456A (is)
MX (1)	MXPA04008999A (is)
NO (1)	NO20044442L (is)
NZ (1)	NZ535365A (is)
PL (1)	PL372413A1 (is)
RS (1)	RS81904A (is)
RU (1)	RU2312857C2 (is)
UA (1)	UA77296C2 (is)
WO (1)	WO2003080047A1 (is)
ZA (1)	ZA200407337B (is)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI329105B (en)	2002-02-01	2010-08-21	Rigel Pharmaceuticals Inc	2,4-pyrimidinediamine compounds and their uses
IL166241A0 (en)	2002-07-29	2006-01-15	Rigel Pharmaceuticals Inc	Method of treating or preventing autoimmune diseases with 2,4-pyrimidinedinediamine compounds
US6916937B2 (en) *	2003-02-03	2005-07-12	Bristol-Myers Squibb Company	Carbohydrate prodrugs of fluorooxindoles
ES2421139T3 (es)	2003-07-30	2013-08-29	Rigel Pharmaceuticals, Inc.	Compuestos de 2,4-pirimidindiamina para su uso en el tratamiento o la prevención de enfermedades autoinmunitarias
US7169803B2 (en) *	2004-03-15	2007-01-30	Bristol-Myers Squibb Company	N-substituted prodrugs of fluorooxindoles
US7253167B2 (en)	2004-06-30	2007-08-07	Bristol-Myers Squibb Company	Tricyclic-heteroaryl compounds useful as kinase inhibitors
US7449458B2 (en)	2005-01-19	2008-11-11	Rigel Pharmaceuticals, Inc.	Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US8227455B2 (en)	2005-04-18	2012-07-24	Rigel Pharmaceuticals, Inc.	Methods of treating cell proliferative disorders
CN101282979B (zh) *	2005-09-13	2011-09-21	卫材R&D管理有限公司	稳定性被改善的含有磷酸氯甲酯衍生物的组合物及其制备方法
TWI385169B (zh)	2005-10-31	2013-02-11	Eisai R&D Man Co Ltd	經雜環取代之吡啶衍生物及含有彼之抗真菌劑
TW200841879A (en) *	2007-04-27	2008-11-01	Eisai R&D Man Co Ltd	Pyridine derivatives substituted by heterocyclic ring and phosphonoamino group, and anti-fungal agent containing same
US8513287B2 (en) *	2007-12-27	2013-08-20	Eisai R&D Management Co., Ltd.	Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same
JP2011511792A (ja) *	2008-02-05	2011-04-14	メルク・シャープ・エンド・ドーム・コーポレイション	Ｃｇｒｐ受容体アンタゴニストのプロドラッグ
US8188119B2 (en)	2008-10-24	2012-05-29	Eisai R&D Management Co., Ltd	Pyridine derivatives substituted with heterocyclic ring and γ-glutamylamino group, and antifungal agents containing same
JP5732453B2 (ja) *	2009-06-25	2015-06-10	アルカーメスファーマアイルランドリミテッド	Ｎｈ酸性化合物のプロドラッグ
PT2445502T (pt)	2009-06-25	2017-09-22	Alkermes Pharma Ireland Ltd	Compostos heterocíclicos para o tratamento de distúrbios neurológicos e psicológicos
NZ604423A (en)	2010-06-24	2015-01-30	Alkermes Pharma Ireland Ltd	Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
ES2734713T3 (es)	2015-07-06	2019-12-11	Gilead Sciences Inc	Moduladores Cot y métodos de utilización de los mismos
AU2019205325A1 (en)	2018-01-05	2020-08-13	Cybrexa 1, Inc.	Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
AU2019230014B2 (en)	2018-03-05	2024-11-28	Alkermes Pharma Ireland Limited	Aripiprazole dosing strategy
JP7849948B2 (ja) *	2018-03-05	2026-04-22	テオンセラピューティクス，インク．	アデノシン受容体アンタゴニストおよびその使用
TWI915558B (zh)	2019-06-14	2026-02-21	美商基利科學股份有限公司	Cot 調節劑及其使用方法
BR112022000297A2 (pt)	2019-07-10	2022-03-15	Cybrexa 3 Inc	Conjugados de peptídeos de agentes de alvo de microtúbulos como terapêuticos
MX2022000449A (es)	2019-07-10	2022-04-25	Cybrexa 2 Inc	Conjugados peptídicos de citotoxinas como terapéuticos.
CA3175541A1 (en)	2020-03-30	2021-10-07	Gilead Sciences, Inc.	Solid forms of (s)-6-(((1-(bicyclo[1.1.1]pentan-1-yl)-1h-1,2,3-triazol-4-yl)2-methyl-1-oxo-1,2- dihydroisoquinolin-5-yl)methyl)))amino)8-chloro-(neopentylamino)quinoline-3-carb onitrile a cot inhibitor compound
EP4126862B1 (en)	2020-04-02	2025-05-21	Gilead Sciences, Inc.	Process for preparing a cot inhibitor compound
EP3912625A1 (en)	2020-05-20	2021-11-24	Kaerus Bioscience Limited	Novel maxi-k potassium channel openers for the treatment of fragile x associated disorders
WO2025233532A1 (en)	2024-05-10	2025-11-13	Les Laboratoires Servier	Maxi-k potassium channel openers and therapeutic applications thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SU749063A1 (ru) *	1979-01-29	1996-09-10	Военно-медицинская академия им.С.М.Кирова	3-(4-карбэтокси)-фенилимино-2-оксоиндолин, повышающий устойчивость организма к повторной черепно-мозговой травме
US5234947A (en)	1991-11-07	1993-08-10	New York University	Potassium channel activating compounds and methods of use thereof
US5187173A (en) *	1991-12-27	1993-02-16	Sterling Winthrop Inc.	2-saccharinylmethyl and 4,5,6,7-tetrahydro-2-saccharinylmethyl phosphates, phosphonates and phosphinates useful as proteolytic enzyme inhibitors and compositions and method of use thereof
US5565483A (en) *	1995-06-07	1996-10-15	Bristol-Myers Squibb Company	3-substituted oxindole derivatives as potassium channel modulators
AU754965B2 (en)	1997-12-31	2002-11-28	University Of Kansas, The	Water soluble prodrugs of tertiary amine containing drugs and methods of making thereof
DK1056754T3 (da) *	1998-01-29	2004-02-16	Bristol Myers Squibb Co	Phosphatderivater af diaryl-1,3,4-oxadiazolon

2003
- 2003-03-20 GE GEAP8458A patent/GEP20074230B/en unknown
- 2003-03-20 IL IL16402203A patent/IL164022A0/xx active IP Right Grant
- 2003-03-20 UA UA20041109513A patent/UA77296C2/uk unknown
- 2003-03-20 EP EP03711659A patent/EP1485085A4/en not_active Withdrawn
- 2003-03-20 HR HRP20040853 patent/HRP20040853A2/xx not_active Application Discontinuation
- 2003-03-20 PL PL03372413A patent/PL372413A1/xx not_active Application Discontinuation
- 2003-03-20 KR KR1020047014626A patent/KR100951499B1/ko not_active Expired - Fee Related
- 2003-03-20 CA CA002479256A patent/CA2479256A1/en not_active Abandoned
- 2003-03-20 MX MXPA04008999A patent/MXPA04008999A/es active IP Right Grant
- 2003-03-20 WO PCT/US2003/008613 patent/WO2003080047A1/en not_active Ceased
- 2003-03-20 RU RU2004131201/04A patent/RU2312857C2/ru not_active IP Right Cessation
- 2003-03-20 RS YUP-819/04A patent/RS81904A/sr unknown
- 2003-03-20 US US10/393,031 patent/US6930100B2/en not_active Expired - Lifetime
- 2003-03-20 BR BR0308737-9A patent/BR0308737A/pt not_active IP Right Cessation
- 2003-03-20 JP JP2003577875A patent/JP4359150B2/ja not_active Expired - Fee Related
- 2003-03-20 NZ NZ535365A patent/NZ535365A/en not_active IP Right Cessation
- 2003-03-20 CN CNB038109778A patent/CN100384820C/zh not_active Expired - Fee Related
2004
- 2004-09-12 IL IL164022A patent/IL164022A/en not_active IP Right Cessation
- 2004-09-13 ZA ZA200407337A patent/ZA200407337B/en unknown
- 2004-09-17 IS IS7456A patent/IS7456A/is unknown
- 2004-09-20 CO CO04093294A patent/CO5611143A2/es not_active Application Discontinuation
- 2004-10-19 NO NO20044442A patent/NO20044442L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
UA77296C2 (en)	2006-11-15
WO2003080047A1 (en)	2003-10-02
CO5611143A2 (es)	2006-02-28
IL164022A (en)	2008-04-13
MXPA04008999A (es)	2004-12-07
KR20040106293A (ko)	2004-12-17
US20030195169A1 (en)	2003-10-16
EP1485085A4 (en)	2007-03-14
BR0308737A (pt)	2005-01-11
RU2312857C2 (ru)	2007-12-20
HRP20040853A2 (en)	2004-12-31
JP2005526097A (ja)	2005-09-02
CN1652769A (zh)	2005-08-10
ZA200407337B (en)	2006-02-22
EP1485085A1 (en)	2004-12-15
JP4359150B2 (ja)	2009-11-04
CA2479256A1 (en)	2003-10-02
GEP20074230B (en)	2007-11-12
CN100384820C (zh)	2008-04-30
PL372413A1 (en)	2005-07-25
RS81904A (sr)	2007-02-05
KR100951499B1 (ko)	2010-04-07
RU2004131201A (ru)	2005-05-10
IL164022A0 (en)	2005-12-18
AU2003215017A1 (en)	2003-10-08
NZ535365A (en)	2006-07-28
US6930100B2 (en)	2005-08-16
NO20044442L (no)	2004-10-19

Publication	Publication Date	Title
HRP20040853A2 (en)	2004-12-31	Phosphate prodrugs of fluorooxindoles
EP1583997A4 (en)	2010-03-24	Photoresist DISTANCE
CY2015015I1 (el)	2020-05-29	Παραγωγη τιακουμυκινης
EP1556052A4 (en)	2006-11-02	MITOTIC KINESINE HEMMER
EP1517904A4 (en)	2007-02-21	INHIBITORS OF MITOTIC KINESINE
EP1509507A4 (en)	2006-09-13	INHIBITORS OF MITOTIC KINESINE
EP1578724A4 (en)	2006-11-29	INHIBITORS OF MITOTIC KINESINE
DE60315809D1 (de)	2007-10-04	Geformtes tampon
EP1581497A4 (en)	2009-03-18	INHIBITORS OF MITOTIC KINESINE
EP1474093A4 (en)	2005-02-16	Granzyme B INHIBITORS
EP1697331A4 (en)	2010-08-04	INHIBITORS OF MITOTIC KINESINE
ITTO20030629A1 (it)	2004-02-18	Procedimento di realizzazione di collegamenti ad
EP1615935A4 (en)	2008-04-23	PHOSPHATE DERIVATIVES
PT1513514E (pt)	2015-02-20	Formulações tópicas de hidroximatairesinol
DE60327447D1 (de)	2009-06-10	Pflaster
NO20055612D0 (no)	2005-11-25	Anti-inflammatoriske fosfonatforbindelser
FR2838437B1 (fr)	2004-06-04	Procedes de preparation de combretastatines
DE50308133D1 (de)	2007-10-18	Ultraschall-stehwellen-zerstäuberanordnung
DE60324196D1 (de)	2008-11-27	Narcistatin-prodrugs
DE10390373D2 (de)	2004-12-09	Phosphorchelatverbindungen
NO20024880L (no)	2003-09-22	Sammensetning inneholdende fosfat
DE60321745D1 (de)	2008-08-07	Multipolarer Magnetogenerator
DE10394115D2 (de)	2005-10-20	Schabewärmetauscher
EP1697381A4 (en)	2009-03-11	INHIBITORS OF MITOTIC KINESINE
DE60307471D1 (de)	2006-09-21	Hemmung